Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical efficacy of relevant PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. حسب Filip Stanicic (17808254)

الموضوعات:

Transepithelial resistance of NHBE decreases significantly after PAA exposure. حسب Ellie S. Burns (21246537)

Effect of different doses (mg/Kg) of the defatted extract (DE) of the leaves of <i>S. malaccense</i> and <i>S. samarangense</i> on serum ALT and AST levels. Data represented as mea... حسب Fatma A. Moharram (9276104)

Mycosis rates (mean % ± SE) of aphids exposed to entomopathogenic fungi from four agroecological zones. حسب Aime Cheoh Enoh (20141758)

الموضوعات:

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. حسب Iratxe Zuazo-Gaztelu (21071939)

Effects of finerenone on the urinary β2-MG levels in all patients. حسب Jia Song (495396)

الموضوعات:

Specifications and effects of heating devices. حسب Xuemei Xiang (20756894)

الموضوعات:

IRE1 depletion decreases heterochromatin, DNA, and H3K9me3 methylation, and UHRF1. حسب Iratxe Zuazo-Gaztelu (21071939)

SBP3 KD decreases cytoadhesion of iRBCs to bovine brain endothelial cells (BBECs). حسب Atefeh Fathi (7370876)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Flowchart of patient selection in this study. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات: